The University of Nottingham Impact Campaign

Centre of Excellence for Autoimmunity in Cancer

Professor Robertson leads CEAC and developed the world’s first blood test for lung cancer. This project will develop new blood tests to detect breast and colon cancer. This will lead to more lives being saved through treatment of patients before tumours have spread.

history Campaign has now closed

It ran from 12:00 PM, 4 December 2015 to 5:00 PM, 14 December 2015

Check mark Match funded

Campaign target

£16,500

Amount raised

£33,000

Donations

22

    Category

  • Education/Training/EmploymentEducation/Training/Employment
  • Hospitals/HospicesHospitals/Hospices
  • Medical ResearchMedical Research

    Helping

Location

  • ‚ÄúA landmark in cancer detection. Its beauty is its simplicity‚Äù.

    — Scotland‚Äôs Chief Medical Officer

  • “A landmark in cancer detection. Its beauty is its simplicity”.

    — Scotland’s Chief Medical Officer

Situation

Worldwide, the number of new cases of cancer is expected to double by 2030. Breast cancer and bowel cancer are the second and third most common types, after lung cancer. Some screening tests are available for breast and bowel cancer but they are limited in their effectiveness and are based on detecting cancers once symptoms have appeared. Our project will design new tests which will mean these cancers can be detected much earlier.

Solution

We will develop blood tests which detect anti-bodies. This allows cancer to be detected at a much earlier stage, improving the likelihood of survival and allowing less aggressive treatments to be used. The blood tests are also much cheaper to administer and more convenient for patients, younger and older. Unlike mammograms, blood tests for breast cancer should work in pre-menopausal women just as well as in post-menopausal women.